Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF) CEO James Lanthier and PharmAla CEO Nick Kadysh join Proactive's Natalie Stoberman to announce their first sale of pharmaceutical grade psilocybin into the Australian market.
Lanthier and Kadysh said the psilocybin is being purchased by Reset Mind Sciences Limited, a Western Australian based company focused on psychedelic medicines, and a subsidiary of ASX-listed Little Green Pharma.
The CEOs added that regulatory developments in Australia have opened the door to more opportunities for their partnership that combines Mindset's novel synthesis processes and PharmAla's sales infrastructure.